Emily Williams, MD, is a psychiatry resident at the University of California, San Francisco in the NIH-funded Resident Research Training Program (R25 MH060482). She is currently conducting an analysis of the effects of MDMA on therapeutic alliance as well as serving as co-PI on a MDMA-assisted psychotherapy for PTSD Phase 3 clinical trial site. Dr. Williams also works as the independent clinical rater for the MAPS-funded study on MDMA for anxiety related to life threatening illness in Marin, CA. And for the second year, she is serving as a mentor at the California Institute of Integral Studies Center for Psychedelic Therapy and Research. In addition to her clinical and research work, she has a passion for harm reduction and serves as a supervisor for the Zendo Project which provides psychedelic harm reduction for events and festivals.